Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

导出原文传递

翻译打印收藏纠错

作者： Ravandi,F. ^[1] ; AranaYi,C. ^[2] ; Cortes,J.E. ^[3] ; Levis,M. ; Faderl,S. ; Garcia-Manero,G. ; Jabbour,E. ; Konopleva,M. ; O'Brien,S. ; Estrov,Z. ; Borthakur,G. ; Thomas,D. ; Pierce,S. ; Brandt,M. ; Pratz,K. ; Luthra,R. ; Andreeff,M. ; Kantarjian,H.

作者单位： Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States ^[1] Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD ^[2] Division of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, United ^[3]

发布时间 2014-09-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览6

Leukemia

2014年28卷7期

1543-1545页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

Leukemia

相似文献

Leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

Leukemia

相似文献

Leukemia

相关期刊

检索历史清除